Brands
Zydus Lifesciences signs exclusive pact with Myriad Genetics to launch cancer tests in India
Ahmedabad: Zydus Lifesciences Limited., an innovation-led life-sciences company with an international presence, has signed an agreement with Myriad Genetics, a leader in molecular diagnostic testing and precision medicine company. Pursuant to the Agreement, Zydus will be introducing MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus, Homologous Recombination Deficiency (HRD) Test and Prolaris® Prostate Cancer Prognostic Test to patients, clinicians, and healthcare systems across India. With the increasing incidence of cancers globally, the MyRisk® Test can help people safeguard their health and take precautionary steps and lifestyle changes that can minimise the risk of cancer. In patients suffering from prostate and ovarian cancers, the Prolaris® Test and MyChoice® HRD Plus Test, respectively, can help patients understand the disease progression and inform the right treatment path.
Commenting on this, Dr. Sharvil P. Patel, Managing Director, Zydus, said, “This agreement marks a major step in expanding access to precision diagnostic tests for cancer treatment in India. The prostate and ovarian cancer tests help doctors with actionable insights to develop personalised treatment plans, predict disease progression, arrive at treatment decisions and streamline clinical workflows. We are also bringing a test which will help identify hereditary risks in patients and their families. Enabling access to these critical diagnostic tests will benefit patients in getting better clinical outcomes and support their fight against cancer.”
Dr. Sharvil P. Patel, Managing Director, Zydus, went on to say, “Reaffirming Zydus’ deep commitment to patient centricity and precision oncology, this collaboration with Myriad Genetics will strengthen clinician education and diagnostic infrastructure so that patients benefit from earlier, more accurate risk assessment and more confident treatment planning. Together, we aspire to make personalised, evidence-based cancer care accessible to every patient who needs it, helping them navigate their journey with greater clarity and support.”
“This collaboration with Zydus is an important step forward in expanding precision oncology across India,” said Brian Donnelly, Chief Commercial Officer for Myriad Genetics. “Myriad tests aim to empower clinicians with actionable information to assess risk, understand tumour biology, and guide truly personalised care with greater clarity, confidence, and hope as they navigate critical health decisions.”
As part of this agreement, Zydus will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics’ broadly validated diagnostic platforms, MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus Test for ovarian cancer, and Prolaris® a gene expression Prostate Cancer Prognostic Test.
These tests have been widely adopted in North America, Europe, and major global cancer centres, and will now empower Indian oncologists with cutting-edge genomic decision-support tools.
The MyRisk® Test is a germline multigene panel for individuals with personal or family history suggestive of hereditary cancer. It detects pathogenic variants in high, moderate and emerging-risk genes to estimate lifetime cancer risk and inform personalised prevention strategies.
The MyRisk® Test is a comprehensive panel which analyses 63 clinically significant genes (BRCA1, BRCA2, PALB2, ATM, TP53, MLH1, MSH2, etc.) covering cancer types like, breast, ovarian, lung, pancreatic, colorectal, endometrial, prostate, gastric, and melanoma. It also includes RiskScore® which combines genetic and clinical data to predict 5-year and lifetime breast cancer risk, enabling individualised screening and prevention plans.
About MyRisk®, MyChoice® HRD Plus and Prolaris®
The MyRisk Hereditary Cancer Test with RiskScore evaluates 63 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for more than 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment individualized to them. The MyRisk® Test can help Indian patients and families identify hereditary cancer risk and plan personalised prevention. This testing would be relevant for: Patients with cancer history (like breast, ovarian, colorectal, endometrial, pancreatic, prostate, melanoma); individuals with strong family history of related or early-onset cancers; or known familial mutation (like BRCA1/2, PALB2, CHEK2, ATM, Lynch genes) and proactive individuals considering risk-reducing surgery, or long-term risk assessment.
The MyChoice® HRD Plus Test is the most comprehensive tumour test for determining HRD status based on the assessment of genomic alterations in genes such as BRCA1 and BRCA2 and Genomic Instability Score (GIS) status using Myriad’s proprietary algorithm. It enables healthcare professionals to identify patients with advanced ovarian cancer who are more likely to respond to treatment with targeted therapies.
The Prolaris® Test is an RNA-based gene expression test that quantifies tumour aggressiveness and provides a patient-specific risk score. The test helps clinicians determine whether active surveillance is appropriate, the need for immediate treatment and a 10-year risk of metastasis and prostate cancer–specific mortality. With prostate cancer incidence rising in India, the Prolaris® Test offers a clinically validated tool for personalised therapy decisions.
Zydus Lifesciences Limited
Zydus Lifesciences Limited is an innovation-led life-sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a global footprint across the United States, India and other international markets. As of September 30, 2025, the group employs 29,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries.
Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs.
Brands
Domino’s Q1 profit falls 6.6 per cent, announces $1 billion buyback
Sales rise 3.4 per cent as pizza giant balances growth and shareholder returns
NEW YORK: Domino’s reported a mixed start to 2026, with first-quarter net income slipping even as global sales and store expansion held steady. The company also announced a fresh $1 billion share buyback, underlining its continued focus on shareholder returns.
Global retail sales rose 3.4 per cent on a constant-currency basis to $4.74 billion. The US remained a key growth engine, with same-store sales inching up 0.9 per cent, supported by a 1.5 per cent rise at company-owned outlets.
International markets, however, painted a more uneven picture. While Domino’s added 161 net new stores overseas during the quarter, international same-store sales declined 0.4 per cent. Overall revenues still climbed 3.5 per cent to $1.15 billion, driven by higher supply chain revenues and a 2.6 per cent increase in food basket pricing for franchisees.
On the profitability front, net income fell 6.6 per cent to $139.8 million, compared to $149.7 million a year earlier. Diluted earnings per share dropped to $4.13 from $4.33. The decline was largely attributed to a $30 million unfavourable swing in unrealised gains linked to its investment in DPC Dash Ltd.
Despite this, operational performance showed resilience. Income from operations rose 9.6 per cent to $230.4 million, supported in part by a $7.8 million pre-tax gain from the sale of a corporate aircraft.
Domino’s footprint continued to expand, with the company ending the quarter at 22,322 stores across more than 90 markets. In the US, digital orders remained dominant, accounting for over 85 per cent of retail sales in 2025.
The company also maintained its dividend payout, declaring $1.99 per share, payable on 30 June 2026. After repurchasing $75.1 million worth of stock during the quarter, the new authorisation lifts the total available for buybacks to $1.29 billion.
Domino’s chief executive officer Russell Weiner said the company’s scale and store-level economics position it well to capture further market share in 2026, even as competition intensifies.
As Domino’s leans into expansion and capital returns, the latest results show a business managing short-term pressures while keeping its long-term growth strategy firmly in play.
